₦airaland Forum

Penboy:
Some of us played Kintara with small money.
But we're up 41 percent.

Over time, big money would flow in.
Please when a call is made here, we do DD and take it to heart.

Just to prove that we don't play here.
Thank you.

Wow happy for you bro, wished my portfolio smiling like yours. Don't worry with time this space will produce millionaires in dollars so we can also give back to our environment. I DON'T DOUBT THIS even with my shishi account.

KTRA premarket+18%


DD applies

Alaska90:
Bro I am grown up man and I take responsibilty for my actions... but in this business sometimes you must not walk alone. Information is key.
So I was just trying to tap your brain for any info. Thanks

So sorry if I sounded harsh, there are some newbies that if u try to tell them something or they don't know what risk they are taking and it doesn't work they way u told them then they will hold it against you. That is why anything I post I put DD applies. You are correct this market needs lots of info which by God grace I will be sharing here but not 100% certain

Needs to share this, we should pay attention to company fillings, all their K filling as this will also help our investment/trading strategies. It will help our decisions either to hold our current position or sell to book our profit/loss and move on

Alaska90:
Could you please share some of your top watch list stocks?
I am also trying to reduce my trading stock to just 5 stocks at a time for an effective trading management

As I stated in my previous post, I trade pennies stocks which i have lined up on my watch list Any time any of them shows the criteria of what am looking for in a stock I enter, I don't have any favorite since am not holding for long but KTRA and FOXO will likely be a long ride for me. But on thing is I do my own thorough findings on any stock before I enter and I tried as much as possible to get stock the stocks at the support level

awesomeJ:
Good evening guys, I'm new here. I tried in the past to open a trading account with brokers in the U.S, But I encountered these two main issues:

1. Most of them wouldn't provide services to Nigerian residents.

2. Most of them seem to charge a flat amount per trade (like $2 per trade) compared to NGX where brokers just take like 1% of value traded. So if I put in an order to buy shares worth $100, and it takes 10 trades to get filled, would they charge me $2 ten times? ($20 total?)


Kindly help with insights.

Also would you say $1000 isn't too lean to test the waters with?

@aremso, I remember you from our investment threads in 2018 thereabouts.

@yok, I remember you from the NGX thread too.

Welcome bamboo will charge you $ 1 minimum irrespective of the volumes you are buying and how many times you are buying it.
1k is a very big money ooo I have a friend that started with 442 and account depleted to 192 so I adviced to sell and book the loss then started afresh at 192 and currently the account is 535 and with the current stock holding am almost certainly certain that the money will double in a few months time. So 1k na big money ooo u can grow it to several thousands of dollars if know what u are doing.

Once KTRA brake 0.16 which is looking to brake now next is 0.19 and at 0.20 FOMO may likely set in


DD applies

I said yesterday or there about that ktra was cheap at the price once it brakes 0.14 next is 0.16.

0.14 broken

DD applies

One of my watch list I underrated had proved me very wrong did 170+% yesterday.

CSSE

Lesson learnt, never underrate any stock in this market

I trade pennies alone and has price range phases which I follow, currently at phase one so I changed as my capital grows. I have over 100 stocks on my watch list this is part of my strategies and am also not holding much stocks my max stocks is 4 at a time and I check on them from time to time to know what has changed. I don't like holding pennies for long but will hold on to those that has potentials and can deliver 100% minimum. In this market sometimes the shorties can make one look stupid and even drop a golden stock. For example my early experience FRQ merger with korro Bio before the final merger conclusion I entered the stock at 0.65 and they shorted the stock to 0.19 I was averaging down till0.41 when I stopped, I was on a loss of 2.2k but the day merger concluded my loss wiped off stock later moved from 14-93. I like health stocks and will consider tech and agric stocks as I watched them on my list. Part of my strategies is to know insiders selling and buying the units they are selling. For those that bought FOXO Technologies am optimistic it will deliver minimum of 100% have also stated the worst case scenario here but either way am still hoping on 100%. When shorties were feasting on KTRA I told a friend I will buy more and she was surprised I will buy when the stock kept going down? I said yes I will buy cos am optimistic 100% minimum is guaranteed here.

Pls apply your DD, nothing in life is sure but GOD do rewards our patience and dedication and believe me many millionaire would be made here with time.

KTRA has 3 critical levels 0.14, 0.16, 0.19. at these levels they will want to short it mad

Pls I have what I look for in a stock and once they meet my criteria I buy and I also state the stocks here, it doesn't mean they will perform to the expectations just follow your mind.

Alaska90:
So you still have hope in foxo?

Bro. Follow your instincts oooo pls follow your risk management don't follow my decision or believe you are the owner of your hard earned money.

Zagee:
We await.

If all they are trying to do works best won't be surprised to see it 1+, VERU carried out a lot of restructuring of their operations and it moved from 0.36 to 1+ and VERU has free float of 112m foxo has 4m+ so might be a nice one in the long run

FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
FOXO Technologies Inc. received a Notice of Non-Compliance from NYSE for failing to file its Annual Report on Form 10-K by the due date. Despite challenges, the company is committed to regaining compliance, improving financial syste
Reaffirms commitment to regaining compliance with the NYSE

MINNEAPOLIS, MN, April 23, 2024 (GLOBE NEWSWIRE) -- On April 17, 2024, FOXO Technologies Inc., a Delaware corporation(the “Company”), received an official notice of noncompliance (the “NYSE American Notice”) from NYSE Regulation (“NYSE”) stating that the Company is not in compliance with NYSE American continued listing standards (the “Filing Delinquency Notification”) due to the failure to timely file the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “Delinquent Report”) by the filing due date of April 16, 2024 (the “Filing Delinquency”).

"Due to significant changes and essential restructuring undertaken in 2023, which has continued in 2024, there has been a delay in filing our Form 10-K," explained Mark White, Interim CEO of Foxo Technologies. "Despite these challenges, we've continued to make considerable operational and financial progress. We are fully dedicated to meeting the NYSE American's continued listing requirements and have implemented measures to greatly improve our financial systems and ensure the highest levels of corporate governance. At the same time, we continue to advance a potentially transformative transaction that we believe would drive significant value for our shareholders. We look forward to providing further updates on this and other positive developments as soon as practical.”

The Company is now subject to the procedures and requirements set forth in Section 1007 of the NYSE American Company Guide. Within five days of the date of the Filing Delinquency Notification, the Company was required to (a) contact the NYSE to discuss the status of the Delinquent Report and (b) issue a press release disclosing the occurrence of the Filing Delinquency, the reason for the Filing Delinquency and, if known, the anticipated date such Filing Delinquency will be cured via the filing or refiling of the applicable report, as the case may be. The NYSE American Notice has no immediate effect on the listing or trading of the Company’s Class A common stock on NYSE American.

During the six-month period from the date of the Filing Delinquency (the "Initial Cure Period", the NYSE will monitor the Company and the status of the Delinquent Report and any subsequent delayed filings, including through contact with the Company, until the Filing Delinquency is cured. If the Company fails to cure the Filing Delinquency within the Initial Cure Period, the NYSE may, in the NYSE’s sole discretion, allow the Company’s securities to be traded for up to an additional six-month period (the "Additional Cure Period" depending on the Company’s specific circumstances. If the NYSE determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the NYSE American Company Guide. If the NYSE determines that an Additional Cure Period of up to six months is appropriate and the Company fails to file its Delinquent Report and any subsequent delayed filings by the end of that period, suspension and delisting procedures will generally commence. An issuer is not eligible to follow the procedures outlined in Section 1009 with respect to these criteria.

Notwithstanding the foregoing, however, the NYSE may in its sole discretion decide (i) not to afford an issuer any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the NYSE believes, in the NYSE’s sole discretion, that continued listing and trading of an issuer's securities on the NYSE is inadvisable or unwarranted in accordance with Sections 1001-1006 hereof.

The Company intends to regain compliance with the NYSE American continued listing standards. There can be no assurance that the Company will ultimately regain compliance with all applicable NYSE American listing standards.

About FOXO Technologies Inc. (“FOXO”)

FOXO is a biotechnology company dedicated to improving human health and longevity through the development of cutting-edge technology and product solutions for various industries, including life insurance. FOXO’s epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. FOXO is committed to leveraging the latest advancements in science and technology to help people live better, longer lives. For more information about FOXO, visit www.foxotechnologies.com.

Forward-Looking Statements

This press release contains certain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein, including statements about the delisting of the Warrants from NYSE American, trading of the Warrants in the over-the-counter market, the continued listing of the Company’s Class A common stock on NYSE American, and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning, but the absence of these words does not mean that a statement is not forward-looking. Any such forward-looking statements are based upon the current beliefs and expectations of the Company’s management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond the Company’s control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the possibility that the Plan will not be accepted by NYSE American, the Company will be unable to satisfy other continued listing requirements of NYSE American for its Class A common stock to maintain the listing of the Class A common stock on NYSE American; the risk of changes in the competitive and highly regulated industries in which FOXO operates; variations in operating performance across competitors or changes in laws and regulations affecting FOXO’s business; the ability to implement FOXO’s business plans, forecasts, and other expectations; the ability to obtain financing; the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans; the enforceability of FOXO’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO operates, including the highly regulated insurance industry. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO’s most recent reports on Forms 10-K and 10-Q, particularly the “Risk Factors” sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:
Crescendo Communications, LLC
(212) 671-1020
foxo@crescendo-ir.com

To me KTRA is cheaper at the current rate, FOMO will soon set in to push it up.


Just my views oo



DD applies

yok:
This should be neutral. Most activity/high volume will take place during normal hours. Just like futures now. It is a 24 hrs market, but bulk of trading takes place when the major markets are opened.

The only risk here is if we attempt to trade when market (US) market 8s not opened, it is extremely risky, you can pay $10 for a $2 stock. So, we need to restrict ourselves to normal market hours. Even for forex, same caution applies, only trade when there would be liquidity in the market.

Thanks bro

NYSE wants to introduce 24/7 trading just like crypto, gurus how can this affect us positively and negatively?

Maybe something coming up soon on FOXO currently gaining 12%

For those holding FOXO, they will likely do RS of 1:10 or 1:15 to meet up with the minimum bidding price and the will bring the free float figures to around 400k or 267k as the case may be and if there is no dilution due to slim float it will deliver 100% gain so be smart to get 100% out before the shorties spoil the show but if you can still hold I believe it will deliver in the long run when the shorts are done with it, it will still go up Wella. For KTRA they will be playing with it till the last month of q3 when the Merger is finalized. That is worst case scenario for FOXO


DD applies

arasayar:
How safe is bamboo for very long term investment say 10yrs, are bamboo customers the actual shareholders recognised in the US stock market or bamboo is?

I don't really know much about them but I think they have a very reliable broker in the US they are working with. Chat them up

Capitas7:
Companies in the Agribusiness subsector might be one to be added to the radar (hold , not buy for now) of a value or dividends portfolio. I was attracted to this sector because of the products category and their dividends generosity. A few negatives:

1. The sector performs poorly when there's nationwide/global supply chain problems.
2. There's constant threat to products - disasters, transportation, storage, etc.
3. Cost of sales is very elastic, and net income fluctuates with inflation and other factors.
4. Growth in stock value rapidly follows growth in earnings, shutting out investors who want to buy on book improvements - rumors are the deal, not news.

Bunge is one to watch - globally large, Canadian NTR is another.

You are right one has been on my radar since, when it gets to my level I will strike.

Zagee:
Definitely watching the charts. As for medical stocks- a goldmine. It's just the gestation period that can be tiring sometimes.


On $CGC, have you been able to make some sense on this new structure its establishing? Best to see it play out to next earnings. What do you think?

CGC will move with time, they will still need to cut a lot of things to strengthen their balance sheet. Gestation period very tiring u are absolutely correct and during that time shorties usually do what they like with it.

Zagee:
Everybody has their strategy. I don't expect people to be holding on to $CGC with the poor result associated to $TILRAY it was bound to get dragged.

On bitcoin, halving was in motion so you can't be tapping it but looking after post halving.

On $Foxo already down, but will be adding to it with my loose cash bit by bit(a long term hold).

Economic data(Inflation cum expected rate hike) will only do what it does best.

Patience and caution! Know your risk tolerance

PS: You don't need to rub it on any body's face.

On FOXO I knew it will go down since it go down since is yet to brake resistance of 0.45 and most likely it will gap down to previous support of 0.25 which it did yesterday and started moving up again. At 0.25+ it was loosing 10% but closed at 5.93% so it will move if their management released press statement or even their q4 2023 it will move for KTRA since it has already done 120% gap up when the news of merger came so they will surely Short it until they are tired by q3 when they finalize their merger it will move. For those that took CGC with me last year it delivered over 180% when it moved from 0.38 to 1.07% was even out before they did their RS. For tilray if they don't produce results that is close to their OS that stock goin no we have left it since. I prefer health sector from day one because no matter what they will have one catalyst or the other that will push them. Clinical trials, FDA approval, Cancer drug success(this can give 2000% gain) Merger or outright sale. So health sector have catalyst that will always push them. FOXO is under health sector and wants to use AI in their operations so is a sleeping giant

yok:
LET US BE READY FOR A TOUGHER MARKET
The unexpected has happened, inflation has won the fight against rate cut expectation.

https://www.investing.com/news/economy/powell-says-recent-inflation-data-point-to-need-to-keep-rates-higher-for-longer-3380757

Now we need to add some shorting to our strategies. So it is back to the drawing board.

We will not panic, now it is the quaterlibg earnings that will determine the next direction of the market. Now the dollar is going to be stronger? What are we to do. Let us face the task of Managing our trades. Trading is serious, this is the reason we should avoid distractions when we are planning our trades.

At a time like this quality of our stocks matter. It is very unfortunate that we will see more people being washed out of the market. So expect some people to become quiet, some people that you see that have made comments may not be able to make comment aga, due to dicipation of their trading capital

that is why I advocate that everyone should have their trading strategies and know the risk u are entering or taking I still bought some units of my target stock today.

For those who can take the risk in KTRA

Support 0.8-0.10 if it brakes 0.11


DD applies

Alaska90:
I am jumping on this too.....please keep us update. Thanks

I even want to buy more exchange rate is my headaches because I pulled some gain out but have determined to grow my account to a certain level before I pull anything out, if it goes down again this week I will enter irrespective of exchange rate as long as 100% is guaranteed on this one by God grace.

DD applies!

Watch this HLTH though have mentioned it here before this time don't buy yet watch out for possible M&A or outright sale, when u see it surging premarket enter for possible 50-100% gain then pull out first. But if you see it at 0.10 enter


DD pls

Alaska90:
I just want to use this to thank you Mr Aremso for your call of this stock. I jumped on it then but I was away for some months due to a family tragedy. I just came back and discovered that I am up over 200% in gain with a new ticker name KORRO
Please keep sharing here your calls and any other useful information
Thanks once again and God bless you more

Thank God you are back, hope everyone in the family is fine now!

yok:
MARKET IS ABOUT TO DO A Reset!!!
As we prepare for the new week, we need to slow down on buying. If nothing unsual happens to keep the bullish expecting alive, we may see the bear on full throttle.

So we should be prepared to take some of out money out of the market (temporarily). Then we should be prepared to start playing on the short side. From the look of things, among the 1st casualty of th8s bearish move may be the Gold stocks.

So, not a time to panic, let us look at our portfolios on Monday/Tuesday, we should see how the market is playing out and then see other sectors that will be bearish (Gold and blockchain industries are pencil led down already).

Wishing all the best, at a time like this no stock is safe, a big bear is likely to bring the prices of most stocks down including the blue chips (you can can check the price chart for: VZ, PSX, T, PFE etc they are I strong downtrend). Agains, conclusion is don't panic, mark down those stocks you need to sell af chats are bearish, not those you are to sell and take profits and you may rebuy at lower price. Losses are normal ( but we should keep them to manageable level, 25% of our purchase price, if you are well diversified this should be around 2% of your portfolio value). This may also be an opportunity for some of us with too many stocks in our portfolio (some have over 40) to look forward to consolidating some of the stocks such that we will have a portfolio that make us to forget that we even have some stocks, only for us to check one day and see that we have a stock that has been falling heavily, which we should have sold long ago).

40 stocks? Those ones be Warren Buffett in the making

I think I mentioned this stock here before

FIXX

They merged with QTTB wit post merger price of around $15, it closed at $28 yesterday almost going to 100% gain and those that have entered at 0.50 before it did RS at 0.88 they should be on 130% gain now.